LRRK2 and diffuse large B-cell lymphoma: At the molecular level, the drug combination of LRRK2‐IN‐1 and birabresib compared to single treatments determined a downregulation of p‐AKT (S473) and LRRK2 itself in the two GCB DLBCL cell lines tested.